Pre-made Sapelizumab benchmark antibody ( Whole mAb, anti-IL6R therapeutic antibody, Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Sapelizumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.
| Products Name (INN Index) | Pre-Made Sapelizumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody |
|---|---|
| INN Name | Sapelizumab |
| Target | IL6R |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2017 |
| Companies | Chugai Pharmaceutical,Roche |
| Conditions Approved | Neuromyelitis optica |
| Conditions Active | NA |
| Conditions Discontinued | Rheumatoid arthritis |
| Development Tech | NA |
| Previous Name | satralizumab |
| Gm Offical Target Name | IL6R |
| Package |
